Ana
Vega Gliemmo
KU Leuven
Lovaina, BélgicaPublicacións en colaboración con investigadores/as de KU Leuven (58)
2023
-
(Pre)treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer
International Journal of Cancer, Vol. 153, Núm. 9, pp. 1579-1591
-
Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants
Nature Genetics, Vol. 55, Núm. 12, pp. 2065-2074
-
Comparing symptom reporting by prostate cancer patients and healthcare professionals in the international multicentre REQUITE study
Radiotherapy and Oncology, Vol. 178
-
Comparison of prone and supine positioning for breast cancer radiotherapy using REQUITE data: dosimetry, acute and two years physician and patient-reported outcomes
Acta Oncologica, Vol. 62, Núm. 9, pp. 1036-1044
-
Contouring variation affects estimates of normal tissue complication probability for breast fibrosis after radiotherapy
Breast, Vol. 72
-
Genome-wide association study of treatment-related toxicity two years following radiotherapy for breast cancer
Radiotherapy and Oncology, Vol. 187
-
Large-scale meta-genome-wide association study reveals common genetic factors linked to radiation-induced acute toxicities across cancer types
JNCI Cancer Spectrum, Vol. 7, Núm. 6
-
Reply to: Comments on “(Pre)treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer”
International Journal of Cancer
2022
-
Erratum: Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (European journal of human genetics : EJHG (2022) 30 3 (349-362))
European journal of human genetics : EJHG
-
High weekly integral dose and larger fraction size increase risk of fatigue and worsening of functional outcomes following radiotherapy for localized prostate cancer
Frontiers in Oncology, Vol. 12
-
Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study)
Lung Cancer, Vol. 166, pp. 228-241
-
Polygenic risk modeling for prediction of epithelial ovarian cancer risk
European journal of human genetics : EJHG, Vol. 30, Núm. 3, pp. 349-362
-
Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score
Prostate cancer and prostatic diseases, Vol. 25, Núm. 4, pp. 755-761
-
The correlation between pre-treatment symptoms, acute and late toxicity and patient-reported health-related quality of life in non-small cell lung cancer patients: Results of the REQUITE study: Symptoms, toxicity and quality of life of lung cancer patients
Radiotherapy and Oncology, Vol. 176, pp. 127-137
-
Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer
Radiotherapy and Oncology, Vol. 168, pp. 75-82
2021
-
A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers
Nature Communications, Vol. 12, Núm. 1
-
A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer
Prostate, Vol. 81, Núm. 10, pp. 683-693
-
Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer
Prostate Cancer and Prostatic Diseases, Vol. 24, Núm. 2, pp. 532-541
-
Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity
Radiotherapy and Oncology, Vol. 159, pp. 241-248
-
Erratum: Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (Nature communications (2021) 12 1 (1078))
Nature communications